Amgen Inc.

William Callahan

Rahul Rajan Kaushik

Richard L Remmele, Jr

Dingjiang Liu

Ramil F Latypov

Gayathri Ratnaswamy

Qahera Munaim

Alona Teran

Nazer Khalaf

Christi L Clogston

Twinkle R Christian

Robert Matthew Fesinmeyer

Joy Brennan

Yael Wexler-cohen

Sai Chakradhar Padala

Stable adalimumab formulations are disclosed.

Anti-TNF alpha antibody formulations

Protein formulations and methods of making and using such formulations are provided herein. The formulation can be an ophthalmic formulation, such as for intravitreal administration. In some embodiments, the formulation comprises a VEGFR-Fc fusion protein, such as aflibercept.

VEGFR-Fc fusion protein formulations

Described herein are therapeutic protein formulations comprising N-methyl pyrrolidone (NMP), methods related to reducing viscosity of pharmaceutical formulations and methods related to stabilizing pharmaceutical formulations using NMP.

Reduced viscosity protein pharmaceutical formulations

The present invention provides stable pharmaceutical compositions of pegylated carfilzomib compounds, methods for preparing the compositions, and uses of the compositions for treating cancer, including hematologic malignancies such as multiple myeloma. The compositions can be stored in frozen form or lyophilized to dry solid form.

Stable compositions of pegylated carfilzomib compounds

The present invention provides long-term stable formulations of a lyophilized therapeutic peptibody and methods for making a lyophilized composition comprising a therapeutic peptibody.

Lyophilized therapeutic peptibody formulations

Growing community of inventors

Thousand Oaks, CA, United States of America

William Callahan